Inhibrx Biosciences, Inc. (INBX)
Healthcare
Biotechnology
82.10 $
-3.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Inhibrx Biosciences, Inc. (INBX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -130 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| -18 | -19 | -23 | -32 | -48 | -80 | -115 | -193 | -194 | -130 | |
| 0.3 | 0.4 | 0.7 | 1.2 | 1.0 | 1.2 | 1.2 | 1.2 | 2.3 | 2.5 | |
| 0.6 | 1.2 | 2.5 | 4.0 | 5.0 | 15 | 20 | 25 | 59 | 11 | |
| -6.3 | 1.0 | 4.2 | 3.5 | 13 | -18 | 3.2 | 15 | 52 | -7.6 | |
| 0.2 | 1.3 | 1.4 | 1.8 | 1.4 | 0.9 | 0.7 | 4.6 | 2.6 | 0.0 | |
| -0.2 | -1.3 | -1.4 | -1.8 | -1.4 | -0.8 | -0.7 | -4.6 | -2.6 | 0.0 | |
| – | 1.4 | 0.8 | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | 0.0 | 100 | |
| 29 | 14 | 13 | 43 | 166 | 84 | 259 | 202 | 72 | 101 | |
| 10 | -6.6 | -11 | 9.4 | 117 | 2.6 | 143 | 4.1 | -125 | -28 | |
| -18 | -20 | -25 | -34 | -49 | -81 | -116 | -198 | -197 | -130 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.